As of 2026-06-14, the EV/EBITDA ratio of Reata Pharmaceuticals Inc (RETA) is -15.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RETA's latest enterprise value is 5,813.45 mil USD. RETA's TTM EBITDA according to its financial statements is -378.12 mil USD. Dividing these 2 quantities gives us the above RETA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.1x - 14.0x | 11.1x |
| Forward P/E multiples | 11.7x - 13.9x | 12.6x |
| Fair Price | (132.66) - (157.21) | (134.13) |
| Upside | -177.0% - -191.2% | -177.8% |
| Date | EV/EBITDA |